FTN Midwest Downgrades Barrier Therapeutics (BTRX) to Neutral
More News related to BTRX
- FTN Midwest Downgrades Barrier Therapeutics (BTRX) to Neutral
- Stiefel Laboratories Announces Expiration of Waiting Period to Acquire Barrier (BTRX)
- Cohen's SAC Capital Cuts Stake in Barrier Therapeutics (BTRX) to 1.21%
- Cohen's SAC Capital Discloses 8% Stake in Barrier Therapeutics (BTRX), Files 13D
- Notable Analyst Rating Changes 6/25: GD, NDAQ, JBL, BP Upgraded; BA, RPM, BTRX Downgraded
More News related to Downgrades
- Keefe, Bruyette & Woods Downgrades First State Bancorporation (FSNM) to Market Perform
- Keefe, Bruyette & Woods Downgrades R&G Financial (RGFC) to Market Perform
FTN Midwest downgrades Barrier Therapeutics (Nasdaq: BTRX) from Buy to Neutral.
Barrier Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of pharmaceutical products in the field of dermatology in the United States.
Related Categories
DowngradesStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
